Drug news
Flutiform delays in EU for treatment approval for Asthma
Mundipharma/Napp filed Flutiform (fluticasone propionate plus formoterol fumarate) for asthma using the decentralised procedure in the EU with the UK as reference state and has now encountered delays in achieving consensus amongst the reference states. A launch in 2011 now looks unlikely although most reference states have found the drug approvable.Skye Pharma is the originator of the drug.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.